Validation study of urinary metabolites as potential biomarkers for prostate cancer detection

Bioanalysis

Volumn 4, Issue 10, 2012, Pages 1175-1183

  Gamagedara, Sanjeewa ^a   Kaczmarek, Anthony T ^b   Jiang, Yongqing ^a   Cheng, Xiaoling ^a   Rupasinghe, Maduka ^a   Ma, Yinfa ^a  

^a MISSOURI UNIVERSITY OF SCIENCE AND TECHNOLOGY   (United States)

^b Central Missouri Urology Clinic   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CREATININE; GLYCEROL 3 PHOSPHATE DEHYDROGENASE; KYNURENINE; PROLINE; PROSTATE SPECIFIC ANTIGEN; URACIL;

ADULT; AGED; ANALYTIC METHOD; ARTICLE; BLADDER CANCER; CANCER DIAGNOSIS; CANCER STAGING; CONTROLLED STUDY; CREATININE URINE LEVEL; DIFFERENTIAL DIAGNOSIS; GLEASON SCORE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MAJOR CLINICAL STUDY; MALE; PROSTATE CANCER; STATISTICAL ANALYSIS; VALIDATION PROCESS;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CASE-CONTROL STUDIES; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CREATININE; DIAGNOSIS, DIFFERENTIAL; FEMALE; GLYCEROPHOSPHATES; HUMANS; KYNURENINE; MALE; METABOLOMICS; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM GRADING; PROLINE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; TANDEM MASS SPECTROMETRY; TUMOR MARKERS, BIOLOGICAL; URACIL; URINARY BLADDER NEOPLASMS;

EID: 84861896039     PISSN: 17576180     EISSN: 17576199     Source Type: Journal    
DOI: 10.4155/bio.12.92     Document Type: Article

References (15)

1. Damber JE, Aus G. Prostate cancer. Lancet 371(9625), 1710-1721 (2008
2. Gronberg H. Prostate cancer epidemiology. Lancet 361(9360), 859-864 (2003
3. Heidenreich A, Aus G, Bolla M et al. EAU guidelines on prostate cancer. Eur. Urol. 53(1), 68-80 (2008
4. Roscigno M, Scattoni V, Bertini R, Pasta A, Montorsi F, Rigatti P. Diagnosis of prostate cancer. State of the art. Minerva Urol. Nefrol. 56(2), 123-145 (2004
5. Thompson IM, Pauler DK, Goodman PJ et al. Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter J.Metabolite in urine may point to high-risk prostate cancer.Science323(5916), 865 (2009 Couzin J. Metabolite in urine may point to high-risk prostate cancer. Science 323(5916), 865 (2009
6. Schiffer E. Biomarkers for prostate cancer. World J. Urol. 25(6), 557-562 (2007
7. Gonzalez BA, Mahesh M, Kim KP et al. Projected cancer risks from computed tomographic scans performed in the United States in 2007. Arch. Intern. Med. 169, 2071-2077 (2009
8. Sreekumar A, Poisson LM, Rajendiran TM et al. Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression. Nature 457(7231), 910-914 (2009
9. Jentzmik F, Stephan C, Miller K et al. Sarcosine in urine after digital rectal examination fails as a marker in prostate cancer detection and identification of aggressive tumours. Eur. Urol. 58(1), 12-18 (2010
10. Cao DL, Ye DW, Zhu Y, Zhang HL, Wang YX, Yao XD. Efforts to resolve the contradictions in early diagnosis of prostate cancer: a comparison of different algorithms of sarcosine in urine. Prostate Cancer Prostatic Dis. 14(2), 166-172 (2011
11. Hewavitharana AK. Re: Florian Jentzmik, Carsten Stephan, Kurt Miller et al. Sarcosine in urine after digital rectal examination fails as a marker in prostate cancer detection and identification of aggressive tumours. Eur. Urol. 58, 12-18; 58, e39-e40; author reply e41-e32 (2010
12. Jiang Y, Cheng X, Wang C, Ma Y. Quantitative determination of sarcosine and related compounds in urinary samples by liquid chromatography with tandem mass spectrometry. Anal. Chem. 82(21), 9022-9027 (2010
13. Gamagedara S, Gibbons S, Ma Y. Investigation of urinary pteridine levels as potential biomarkers for noninvasive diagnosis of cancer. Clin. Chim Acta 412(1-2), 120-128 (2011
14. Gamagedara S, Ma Y. Biomarker analysis for prostate cancer diagnosis using LC-MS and CE-MS. Bioanalysis 3(18), 2129-2142 (2011
15. Bales JR, Sadler PJ, Nicholson JK, Timbrell JA. Urinary excretion of acetaminophen and its metabolites as studied by proton NMR spectroscopy. Clin. Chem. 30(10), 1631-1636 (1984